Ensuring Ethical Publication of Clinical Trials Through GPP Guidelines

Introduction to GPP: Why Ethical Publication Matters

Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).

These guidelines aim to promote transparency, responsible authorship, and ethical sponsor engagement in the publication of clinical trial data. GPP applies to pharmaceutical companies, contract research organizations (CROs), academic collaborators, and medical writers involved in the publication planning and dissemination process.

Core Principles of GPP3

GPP3 outlines the ethical standards and operational expectations for preparing and publishing trial-related manuscripts. Core principles include:

• Transparency: Disclose sponsor involvement, funding sources, and data access rights clearly.
• Accountability: Ensure all listed authors meet the ICMJE authorship criteria.
• Accuracy: Report trial results honestly, without bias, spin, or data manipulation.
• Timeliness: Publish results in a timely manner consistent with regulatory disclosure timelines.
• Respect for contributors: Acknowledge the roles of statisticians, writers, and investigators.

These standards align with ICMJE’s Uniform Requirements and complement regulatory requirements from FDA, EMA, and WHO registries.

Authorship Ethics: Avoiding Misconduct

One of the most critical elements in ethical publishing is defining who qualifies as an author. According to both GPP and ICMJE guidelines, authors must meet all of the following criteria:

• Substantial contribution to study design, data analysis, or interpretation
• Drafting or revising the article critically for intellectual content
• Approval of the final version for publication
• Accountability for the accuracy and integrity of the published content

GPP3 strongly discourages ghostwriting—where individuals contribute without acknowledgment—or guest authorship—where individuals are credited without meaningful contribution. Both practices are considered publication misconduct.

Managing Sponsor Involvement and Independence

Sponsors often fund and manage trials, but their role in publication must be disclosed and regulated. Ethical sponsor practices include:

• Allowing authors full access to data or summary-level analyses
• Refraining from controlling the publication’s message or conclusions
• Disclosing conflicts of interest (COIs) related to employment, funding, or stock ownership
• Ensuring transparency about editorial assistance from medical writers

Example: In a multi-site trial on a novel anticoagulant, the sponsor may support writing through an external medical communication agency. However, all authors should approve the content, and the writer’s name and funding source must be disclosed.

Publication Planning and Documentation

Ethical publication also involves organized planning. GPP3 recommends sponsors and authors collaboratively develop a publication plan that includes:

• A publication timeline linked to trial milestones (e.g., database lock, CSR finalization)
• A list of planned abstracts, posters, and manuscripts
• Defined roles and responsibilities for each author and contributor
• A process for conflict resolution and content approval

Publication plans help avoid publication bias by documenting the intent to publish all prespecified outcomes, regardless of result significance. Many sponsors now maintain internal SOPs to govern these workflows.

External Guidelines Complementing GPP

GPP guidelines work in tandem with several other international frameworks:

• EU CTR: Requires summary results and layperson summaries within 12 months of trial completion
• FDAAA 801: Mandates results reporting on ClinicalTrials.gov
• ICMJE: Sets criteria for authorship and trial registration
• WHO ICTRP: Advocates for global result disclosure standards

GPP-compliant sponsors should ensure their practices do not contradict these overlapping obligations.

Role of Medical Writers and Review Committees

Medical writers play an integral role in transforming complex trial data into clear, accurate, and ethical publications. GPP encourages acknowledgment of their work and insists on:

• Documentation of writing contributions in the manuscript or submission form
• Verification that writers had no role in data manipulation or outcome shaping
• Confirmation that writers received direction from authors, not solely from the sponsor

Meanwhile, publication review committees (PRCs) at many organizations ensure that all manuscripts meet internal quality standards and GPP principles before journal submission.

Common Violations and Their Consequences

GPP violations can lead to severe reputational and regulatory consequences. Common violations include:

• Failing to disclose sponsor involvement
• Publishing only favorable outcomes (publication bias)
• Suppressing trial data or delaying negative result publication
• Adding honorary or ghost authors
• Not declaring writer contributions or financial support

Example: In a 2020 audit of 75 industry-sponsored trials published in top journals, over 20% failed to disclose medical writing support—despite involvement. Journals like The Lancet and BMJ have since tightened disclosure policies.

Conclusion: Making GPP a Standard Practice

The GPP guidelines represent a foundational framework for ethical trial result publication. Implementing GPP practices not only ensures compliance but fosters trust among peers, regulators, patients, and the public. Sponsors, CROs, and academic institutions should integrate GPP into their publication SOPs, training, and governance systems.

As clinical trial disclosure becomes increasingly regulated, ethical publication isn’t just a best practice—it’s a moral, scientific, and legal imperative. Upholding GPP principles safeguards the value of medical research and protects the patients whose participation makes it possible.

How to Choose the Best Journal for Your Clinical Trial Publication

Publishing clinical trial results in the right journal can amplify the scientific impact, meet sponsor expectations, and comply with regulatory requirements. But with thousands of journals available, targeting the best one requires a strategic and systematic approach. This tutorial provides a step-by-step guide to help pharma professionals and clinical trial experts select the most suitable journal for their manuscript submission.

As part of the broader scientific and regulatory documentation framework supported by platforms like StabilityStudies.in, journal targeting plays a vital role in scientific communication and evidence dissemination.

Step 1: Understand the Study’s Scope and Relevance:

Start by analyzing the clinical trial’s therapeutic area, phase, intervention type, patient population, and outcome significance. These factors determine journal eligibility and reader interest.

• Is the trial early-phase or confirmatory?
• Does it address a high-burden disease area?
• Are the results statistically and clinically significant?
• Do findings introduce a novel mechanism, therapy, or comparison?

Understanding your trial’s scientific value helps align it with journals that publish similar content.

Step 2: Define the Target Audience:

Identify who should read your published results—clinicians, regulatory experts, policy makers, researchers, or industry sponsors.

1. If targeting practitioners, choose clinically oriented journals
2. If appealing to regulators or payers, opt for policy or pharmacoeconomic journals
3. If focusing on academic or investigational audiences, consider specialty or basic science journals

Matching audience expectations with journal readership improves reach and engagement.

Step 3: Search and Shortlist Candidate Journals:

Use databases like PubMed, Scopus, and Web of Science to find journals that have published studies similar to yours. Review where competitors or peers have published.

Key selection parameters include:

• Impact factor and citation metrics
• Journal scope and topic fit
• Publication frequency and backlog
• Open access availability
• Acceptance rate and review timelines

Document your findings in a comparison table for decision-making.

Step 4: Review the Author Guidelines:

Every journal has detailed instructions for manuscript format, word count, references, ethical compliance, and data presentation.

• Check maximum length for articles and abstracts
• Understand reference citation style (e.g., AMA, Vancouver)
• Review figure/table limits and resolution requirements
• See if the journal accepts supplements or online appendices

Align your manuscript template with the guidelines early to avoid rework.

Step 5: Consider Open Access vs. Subscription Journals:

Open access journals make articles freely available, potentially increasing visibility and citations. However, they often charge article processing fees (APCs).

Evaluate the pros and cons:

1. Open access journals promote global reach
2. Subscription journals may have higher impact factors
3. Hybrid journals offer both options
4. Some sponsors or institutions fund APCs for open access

Ensure transparency in cost disclosures and funding acknowledgments.

Step 6: Ensure Ethical and Regulatory Fit:

Target journals that uphold ethical standards and align with CDSCO or USFDA publishing norms.

• Require trial registration (e.g., ClinicalTrials.gov)
• Comply with ICMJE authorship rules
• Support CONSORT/PRISMA reporting guidelines
• Accept redacted CSRs and data transparency policies

This ensures that your publication meets both scientific and regulatory expectations.

Step 7: Evaluate Journal Review Timelines and Processes:

Some journals offer fast-track options, especially for high-impact or time-sensitive trials. Review the journal’s peer review process for transparency and timeliness.

Consider:

• Time from submission to decision
• Availability of preprints or online-first publishing
• Level of editorial support or language editing
• Revision requirements and reviewer response expectations

Avoid journals with lengthy or unclear processes if speed is critical.

Step 8: Use Journal Match Tools:

Several tools help identify journals based on abstract, title, or keywords:

• Elsevier Journal Finder
• Springer Journal Suggester
• JANE (Journal/Author Name Estimator)
• Wiley Journal Finder

These tools improve accuracy in journal targeting and can complement manual search strategies.

Step 9: Avoid Predatory Journals:

Be cautious of journals that promise fast publication without rigorous peer review. Check the Beall’s List or consult institutional publishing guidelines.

Red flags include:

• No clear peer-review policy
• Unrealistic timelines (e.g., 24 hours to publish)
• Unverifiable editorial board
• Generic or spam-like emails inviting submissions

Maintain credibility by publishing only in recognized, indexed journals.

Step 10: Finalize and Submit:

After shortlisting, rank journals based on fit, quality, timelines, and feasibility. Submit to your first-choice journal, ensuring all components are ready:

• Cover letter with study highlights and journal alignment
• Manuscript formatted to guidelines
• Declarations and ethical approvals
• ICMJE forms or disclosures as needed

If rejected, revise and resubmit promptly to the next journal on your list.

Conclusion:

Choosing the right journal for your clinical trial publication is a critical step in the scientific communication lifecycle. By systematically evaluating scope, audience, ethical fit, timelines, and indexing status, pharma professionals can enhance visibility, citations, and regulatory value. Align this approach with structured documentation frameworks like those in pharma validation and pharma regulatory compliance for long-term publishing success.